Next Article in Journal
Ethnic Stereotype Formation and Its Impact on Sojourner Adaptation: A Case of “Belt and Road” Chinese Migrant Workers in Montenegro
Previous Article in Journal
Gambling-Related Harms for Affected Others: A Finnish Population-Based Survey
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Tuberculosis Notification Trends and Treatment Outcomes in Penitentiary and Civilian Health Care Sectors in the WHO European Region

1
Regional Office for Europe, World Health Organization, 2100 Copenhagen, Denmark
2
Health Primary Care Department, University of Medicine and Pharmacy ‘N. Testemitanu’, 2004 Chisinau, Moldova
3
Main Medical Department of the Ministry of Justice of Azerbaijan Republic, Baku AZ1000, Azerbaijan
4
WHO Collaborating Centre on Prevention and Control of TB in Prisons, Baku AZ1000, Azerbaijan
5
Council for Preventing and Eliminating Discrimination and Ensuring Equality, 2004 Chisinau, Moldova
6
United States Agency for International Development, Arlington, VA 22202, USA
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(18), 9566; https://doi.org/10.3390/ijerph18189566
Submission received: 29 July 2021 / Revised: 6 September 2021 / Accepted: 7 September 2021 / Published: 10 September 2021

Abstract

:
Setting: Tuberculosis (TB) morbidity in penitentiary sectors is one of the major barriers to ending TB in the World Health Organization (WHO) European Region. Objectives and design: a comparative analysis of TB notification rates during 2014–2018 and of treatment outcomes in the civilian and penitentiary sectors in the WHO European Region, with an assessment of risks of developing TB among people experience incarceration. Results: in the WHO European Region, incident TB rates in inmates were 4–24 times higher than in the civilian population. In 12 eastern Europe and central Asia (EECA) countries, inmates compared to civilians had higher relative risks of developing TB (RR = 25) than in the rest of the region (RR = 11), with the highest rates reported in inmates in Azerbaijan, Kazakhstan, Kyrgyzstan, Republic of Moldova, Russian Federation, and Ukraine. The average annual change in TB notification rates between 2014 and 2018 was −7.0% in the civilian sector and −10.9% in the penitentiary sector. A total of 15 countries achieved treatment success rates of over 85% for new penitentiary sector TB patients, the target for the WHO European Region. In 10 countries, there were no significant differences in treatment outcomes between civilian and penitentiary sectors. Conclusion: 42 out of 53 (79%) WHO European Region countries reported TB data for the selected time periods. Most countries in the region achieved a substantial decline in TB burden in prisons, which indicates the effectiveness of recent interventions in correctional institutions. Nevertheless, people who experience incarceration remain an at-risk population for acquiring infection, developing active disease and unfavourable treatment outcomes. Therefore, TB prevention and care practices in inmates need to be improved.

1. Introduction

In 2019 in the world, 10 million people developed TB disease, and 1.4 million died from TB. Although WHO European Region carries only 3% of the global burden of tuberculosis (TB), it has one of the highest proportions of multidrug-resistant TB (MDR-TB). In 2019, an estimated 246,000 incident TB cases occurred in countries of the WHO European Region, equivalent to an average incidence of 26 cases per 100,000 population [1].
Over the last century, global control efforts have reduced the worldwide burden of tuberculosis (TB) [1]. Nevertheless, TB morbidity in the penitentiary sector (The term “penitentiary sector” includes jails, remand/detention/pre-trial centres and prisons) remain a significant barrier to ending TB in the World Health Organization (WHO) European Region by 2030 [1,2]. Worldwide, more than 10 million people are inmates, with around half located in Brazil, China, the Russian Federation and the United States of America [3,4]. According to the United Nations’ estimates of national population levels, the known prison population of the world increased by 3.7% between 2015 and 2018. In the WHO European Region, the most substantial increases in prison populations were observed in Turkey (an increase of 31%), Belarus (19%) and Italy (14%). However, prison populations decreased in Romania (a decrease of 22%), Ukraine (19%) and the Russian Federation (10%) during the same period [5].
TB prevention and care services in prisons are described as often being inadequate and poorly integrated with civilian services, and prison inmates consistently have higher risks of developing active TB and dying from TB than the general population, owing to poor conditions in prisons, such as overcrowding, inadequate ventilation, malnutrition, poor hygiene and poor health care [6,7,8,9,10,11,12]. Additionally, inmates often come from communities, which are at an increased risk of TB or HIV infections [2,8,13].
The objectives of this study were to describe the diversity of notification of incident TB cases (notification rate of incident TB cases—number of new and relapse tuberculosis cases registered and reported per 100,000 population [1]) and their trends in the civilian and penitentiary sectors between 2014 and 2018; the treatment outcomes in the penitentiary versus the civilian sectors, and to estimate the relative risks of developing active TB for prison inmates (inmates—includes people experience incarceration, detainees and convicts) in comparison to civilian population in the WHO European Region.

2. Methods and Materials

This is a retrospective descriptive study analysing magnitude and time-series trends in the notification of new and relapse TB cases and TB treatment outcomes in the civilian and penitentiary sectors in the WHO European Region, based on data reported by WHO European Region Member States to The WHO global TB data collection system [14] between 2012 and 2018, inclusively.

2.1. Setting

The WHO European Region consists of 53 Member States covering a vast geographical region from the Atlantic to the Pacific oceans and from the Mediterranean to the Baltic Sea [15]. Our study focused on comparative analyses of TB indicators in eastern Europe and central Asia (EECA) countries as well as of those from the rest of the region. The EECA region is made up of 12 of the 15 countries, which were formerly part of the Soviet Union, excluding the Baltics, and which are located in the east of the WHO European Region.

2.2. Study Population and Design

Data were collected for new and relapse TB cases and their outcomes from the civilian and penitentiary sectors reported in WHO European Region countries. Three selection criteria were applied: (1) countries that provided at least one report on new and relapse TB cases in both the civilian and penitentiary sectors between 2014 and 2018; (2) countries that provided at least two data points on new and relapse TB cases in both civilian and penitentiary sectors between 2014 and 2019 for enabling analysis of the trend; (3) countries that reported outcomes for TB cases on first-line drug (FLD) treatment schemes in both the civilian and penitentiary sectors for at least one cohort between 2012 and 2016.

2.3. Data Variables and Sources

Data were obtained from 3 sources: (1) The WHO global TB data collection system [14] has an extended set of indicators for TB in European Region prisons, and data were extracted on: prison populations, the numbers of new and relapse TB cases in the civilian and penitentiary sectors for 2014 to 2018, and treatment outcomes for patients on FLD treatment schemes in the civilian and penitentiary sectors for 2012 to 2016; (2) total population estimates were extracted from World Population Prospects [16]; and (3) prison population estimates were taken from the World Prison Brief [17] for countries whose prison population data were missing from The WHO global TB data collection system.

2.4. Analysis and Statistics

For each country, we calculated annual notification rates per 100,000 population of new and relapse tuberculosis cases in civilian and penitentiary sectors separately. The Average Annual Percent Change (AAPC) was calculated by fitting a least-squares regression line to the natural logarithm of the rates, using the calendar year as a regressor variable.
As a measure of the effect of exposure to a prison setting on the risk of development of TB we computed the Relative Risk of TB in prison in reference to the civilian population and the corresponding confidence interval. Results were considered significant if the confidence interval did not include 1. The statistical analysis was performed using the online calculator VassarStats [18]. TB patients who were successfully treated or completed TB treatment were considered to have a favourable outcome; those who failed to complete treatment, were lost to follow-up or who died during the TB treatment were considered to have an unfavourable outcome, as per WHO standard definitions [19]. TB cases with no reported treatment outcomes were excluded from the analysis. We analysed the notification rate of incident TB cases and TB treatment outcomes (unfavourable versus favourable) for the civilian and penitentiary sectors.

3. Results

3.1. Notification Rate of Incident TB Cases and Relative Risks of Developing TB Disease in the Penitentiary Sector Compared with the Civilian Sector

Out of the 53 countries of the WHO European Region, 42, including 10 from the EECA region, reported the number of new and relapse TB cases in the civilian and penitentiary sectors at least once in the five-year period between 2014 and 2018. During this time, 11 (21%) countries did not provide any reports on TB in prisons (Table 1 and Figure 1).
Table 2 shows the notification rate of incident TB cases (The notification rate of incident TB cases is the number of new and relapse tuberculosis cases reported per 100,000 population [1]) and percentage annual changes in notification rate of incident TB cases in the civilian and penitentiary sectors during 2014–2018 for the countries included in this study. In the penitentiary sectors of seven countries, all of which are in the EECA region, incident TB rates of more than 1000 per 100,000 population were reported: Azerbaijan, Kazakhstan, Kyrgyzstan, the Republic of Moldova, the Russian Federation, Tajikistan and Ukraine (Table 2 and Figure 2).
There was observed a decreasing trend in the notification of new TB cases and relapses both in the penitentiary and in the civil sector in 2014–2018 (Table 2 and Figure 3).
In the 42 countries analysed, the average annual change in incident TB rates during the study period was −7.0% in the civilian sector and −10.9% in the penitentiary sector. The decline in incident TB rates among inmates in the nine EECA countries included in this study should be noted (from −6.0% in Kyrgyzstan to −16.5% in Georgia) (Table 2).
TB cases registered in prison’s inmates accounted for approximately 7% for all notified new and relapse TB patients in EECA countries, with the highest level in the Russian Federation (10%); in comparison, in the other countries in the region the proportion was 1.5%, with the highest level in Slovakia (6.3%) in 2014–2018.
Prison’s inmates in the Russian Federation and Slovakia had the highest risks of developing an active TB disease compared with their respective civilian populations (RR = 25, confidence interval CI: 25–26, and RR = 57 (CI: 35–92)), respectively, in the last reported year. (Table 3 and Figure 4).

3.2. Treatment Outcomes in TB Patients on First-Line Drug (FLD) Treatment Schemes

A total of 39 (74%) countries in the WHO European Region reported treatment outcomes for at least one cohort of TB patients, both civilians and inmates, who started on one of the FLD treatment schemes between 2012 and 2016 (Table 1 and Figure 1). Table 4 shows both the favourable and unfavourable treatment outcomes for civilians and inmates in these 39 countries.
Our study highlights a few countries where there were higher levels of unfavourable outcomes for inmates when compared with civilians, for example, Cyprus (100% vs. 0%), the Netherlands (29% vs. 9%) and Kazakhstan (21% vs. 9%). On the other hand, a higher proportion of unfavourable treatment outcomes among civilians than among inmates had been registered in the Czech Republic (28% vs. 8%), Andorra (25% vs. 0%), Estonia (20% vs. 0%), Armenia (19% vs. 0%), and Slovenia (16% vs. 0%).
A total of 12 of the 39 countries achieved TB treatment success rates of over 85% among inmates. In two EECA countries, Belarus and Tajikistan and in five other countries, Bulgaria, Latvia, Montenegro, Romania, Slovakia, the favourable outcomes were more than 85% in both sectors civilian and penitentiary.

4. Discussion

Recent systematic review by Cords et al. revealed a concerning scale of TB burden among people experiencing incarceration in different parts of the world and highlighted the high risk of contracting M tuberculosis infection and developing active disease, compared to the general population [12].
This is the first standardized study on TB morbidity and its treatment outcomes monitoring in the penitentiary sectors of such a scale in the WHO European Region. The main finding of our study is that from 2014 to 2018 the annual incident TB notification rates in prisons across the European Region decreased much faster than in the civilian population, which most likely reflects the decline of true burden in the prison populations. This finding highlights the positive impacts of the TB control interventions carried out by national governments, with the support of international agencies [20,21]. Another finding of our study is that, even though the annual decline of the TB burden in WHO European Region prisons was faster than in the civilian sector, the risk of developing TB disease in prisons is up to 57 times higher compared to the civilian sector. The increased risk of TB for inmates in EECA countries is a known feature of the region and has been previously described in several studies [11,22,23,24]. High prevalence of active TB disease in correctional facilities is fuelled by intra-institutional transmission due to prolonged stays in overcrowded facilities with poor ventilation, along with risk factors, which amplify the risk of TB disease, such as HIV, malnutrition, diabetes, smoking, a history of alcohol and illicit drug consumption, and former TB disease [9,10,25,26]. Theoretically, prison settings offer great opportunities for TB control, and there are practical examples from the region’s prisons in which significant improvements in their TB and rifampicin-resistant-TB burdens have been reported, and WHO-recommended screening, diagnostics, treatment, and linkage to civilian health care is ensured [27,28,29,30]. The high TB morbidity rates in the region’s prisons, of up to 1623 per 100,000 population in 2018, underline the need for substantial improvements in TB control among inmates through wider application of the best practices in the field.
In the majority of EECA countries, treatment success rates for TB in inmates were lower compared with rates in civilian populations, which was not evident for the other countries in the region. This emphasizes the critical need for improvements in the TB services available to inmates. Although the specific reasons for unfavourable treatment outcomes in inmates were not analysed in this study, there is evidence that high drug-resistance rates, insufficient laboratory diagnosis capacities and weak integrations between civilian and prison healthcare services, including ensuring the continuity of TB treatment after release from prison, are major factors leading to poor treatment outcomes in prisons [6,31].
Decarceration and other countries’ justice reforms that lead to it would reduce overcrowding, which is a major environmental factor for tuberculosis transmission, and would significantly reduce TB burden and its rising rates in prisons. Meanwhile, improving the TB situation and treatment outcomes for inmates can only be achieved with governmental commitment, inter-department cooperation for ensuring interventions equivalent to those in the civilian system and in close collaboration with it, and partnerships with civil society organizations. National tuberculosis programmes (NTPs) should develop operational plans and policies that optimize TB control in prisons and for inmates after their release and strengthen the capacities of prison health units for TB case management. Improving treatment outcomes for inmates will also prevent transmission of disease to other inmates, prison staff and community members. The End TB Strategy goals [32] will not be met without the implementation of effective measures in prisons where there are a large number of people who are vulnerable to TB and who engage in behaviours, which also put them at high risk for HIV infection.
One of the limitations of our current study is immediately apparent from the observation of the poor reporting of TB in prisons: in the 5-year study period, there was no available data for 11 WHO European Region countries. In addition, huge fluctuations in the reported annual incident TB rates in prisons reflect uncontrolled epidemics. It is important to note that poor TB reporting affects TB morbidity statistics and, consequently, TB estimates at national and international levels.
This study revealed that some high TB burden countries, such as Turkmenistan and Uzbekistan, have not reported any TB cases among inmates. Cooperation between the institutions responsible for health care in penitentiary systems and the ministries of health should further improve to allow proper TB recording and reporting in both the civilian and penitentiary systems of all countries in the WHO European Region.

5. Conclusions

This review provides an overview of active TB in prisons in the WHO European Region. The completeness of TB reporting for prisons by NTPs was 79% (42 out of 53 countries from the WHO European Region). Our analysis highlights the vulnerability of inmates to TB and emphasises the necessity of improving TB prevention and care policies and their practical application in prisons with respect to active TB detection, infection control, TB treatment and continuity of care. Most countries achieved a substantial decline of TB burden in prisons, which indicates the effectiveness of recent interventions in correctional institutions. These results provide the basis for an understanding that TB prevention and care in prisons should be elevated to be a health care priority and should facilitate intersectional collaboration between civilian health authorities and prison administrations to enable ending TB in the WHO European Region.

5.1. Supporting Information Captions

5.1.1. Evidence Available Prior to This Study

TB surveillance data from the WHO European Region were collected annually from countries via The WHO global TB data collection system [14]. The WHO Regional Office for Europe and the European Centre for Disease Prevention and Control (ECDC) have jointly coordinated the collection and analysis of TB surveillance data in the WHO European Region, aiming to ensure data timeline consistency and comparability, pan-European coverage and avoidance of data duplication [1].

5.1.2. Added Value of the Study

This article provides a full cascade analysis of the TB burden and treatment outcomes at the regional level, designated by countries and subregional groupings.

5.1.3. Implications of All Available Evidence

Further efforts should be made to reduce TB infection transmission, the development of active TB and acquisition of data on treatment outcomes either via WHO data collection or reports from individual countries. In particular, more attention needs to be placed on addressing the known risk factors associated with TB.

Author Contributions

A.D., S.A. and M.D. prepared the study aims. All authors participated in the design, discussion of the results interpretation, read, edited and agreed with the decision to submit the final version of the paper. A.D., A.C., A.H., N.A. and O.K. designed and executed the analysis. A.D. and A.C. led the data collection and reference reviews. A.C. and A.D. wrote the first draft of the manuscript, and A.H., N.A., E.G., S.D., R.M., O.G., S.A. and M.D. provided substantial revisions to the initial version of the manuscript. M.D. provided substantial revisions to the advanced version of the manuscript. A.D. All authors have read and agreed to the published version of the manuscript.

Funding

This analysis was funded by the United States Agency for International Development via WHO consolidated grant GHA-G-00-09-00003.

Institutional Review Board Statement

We used secondary, aggregated (not case based) data, available on the public domain of WHO. Collection of these data collected is granted by the WHO member states and induced by the resolution EB134.R4 of the 134th session of the World Health Assembly.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data available in a publicly accessible repository hosted by WHO https://www.who.int/teams/global-tuberculosis-programme/data. (accessed on 12 June 2021).

Acknowledgments

The authors thank the national TB counterparts in the WHO European Region, including the nominated operational contact points for TB surveillance in the Member States of the WHO European Region for providing data for this analysis based on the WHO mandate for surveillance and response monitoring of the End TB Strategy implementation.

Conflicts of Interest

None of the authors have conflict of interest to declare. The views and opinions expressed in this paper are those of the authors and not necessarily the views and decisions or policies of the World Health Organization, and/or the United States Agency for International Development. The designations used and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO and USAID concerning the legal status of any country, territory, city or area or of its authorities, nor concerning the delimitation of its frontiers or boundaries.

References

  1. WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Tuberculosis Surveillance and Monitoring in Europe 2021—2019 Data; WHO Regional Office for Europe: Copenhagen, Denmark, 2021; Available online: https://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/publications/2021/tuberculosis-surveillance-and-monitoring-in-europe-2021-2019-data (accessed on 12 June 2021).
  2. USAID. Tuberculosis in Prisons: A Growing Public Health Challenge; United States Agency for International Development: Washington, DC, USA, 2013. [Google Scholar]
  3. Coyle, A.; Heard, C.; Fair, H. Detention: Addressing the human cost. Current trends and practices in the use of imprisonment. Int. Rev. Red Cross 2016, 98, 761–781. [Google Scholar] [CrossRef] [Green Version]
  4. Walmsley, R. World Prison Population List, 11th ed.; Institute for Criminal Policy Research: London, UK, 2015. [Google Scholar]
  5. Walmsley, R. World Prison Population List, 12th ed.; Institute for Criminal Policy Research: London, UK, 2018; Available online: http://www.prisonstudies.org/sites/default/files/resources/downloads/wppl_12.pdf (accessed on 12 June 2021).
  6. Dara, M.; Acosta, C.D.; Melchers, N.V.; Al-Darraji, H.A.; Chorgoliani, D.; Reyes, H. Tuberculosis control in prisons: Current situation and research gaps. Int. J. Infect. Dis. 2015, 32, 111–117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Dara, M.; Chadha, S.S.; Melchers, N.V.; van den Hombergh, J.; Gurbanova, E.; Al-Darraji, H.; Van Der Meer, J.B.W. Time to act to prevent and control tuberculosis among inmates. Int. J. Tuberc. Lung Dis. 2013, 17, 4–5. [Google Scholar] [CrossRef]
  8. Baussano, I.; Williams, B.G.; Nunn, P. Tuberculosis incidence in prisons: A systematic review. PLoS Med. 2010, 7, e1000381. [Google Scholar] [CrossRef] [PubMed]
  9. Winetsky, D.E.; Almukhamedov, O.; Pulatov, D.; Vezhnina, N.; Dooronbekova, A.; Zhussupov, B. Prevalence, risk factors and social context of active pulmonary tuberculosis among prison inmates in Tajikistan. PLoS ONE 2014, 9, e86046. [Google Scholar]
  10. Alavi, S.M.; Bakhtiarinia, P.; Eghtesad, M.; Albaji, A.; Salmanzadeh, S. A comparative study on the prevalence and risk factors of tuberculosis among the prisoners in Khuzestan, South-West Iran. Jundishapur J. Microbiol. 2014, 7, e18872. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Stuckler, D.; Basu, S.; McKee, M.; King, L. Mass incarceration can explain population increases in TB and multidrug-resistant TB in European and central Asian countries. Proc. Natl. Acad. Sci. USA 2008, 105, 13280–13285. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Cords, O.; Martinez, L.; Warren, J.L.; O’Marr, J.M.; Walter, K.S.; Cohen, T.; Zheng, J.; Ko, A.I.; Croda, J.; Andrews, J.R. Incidence and prevalence of tuberculosis in incarcerated populations: A systematic review and meta-analysis. Lancet Public Health 2021, 6, e300–e308. [Google Scholar] [CrossRef]
  13. Aerts, A.; Hauer, B.; Wanlin, M. Tuberculosis and tuberculosis control in European prisons. Int. J. Tuberc. Lung Dis. 2006, 10, 1215–1223. [Google Scholar] [PubMed]
  14. WHO. The WHO Global TB Data Collection System; World Health Organization: Geneva, Switzerland, 2021; Available online: https://extranet.who.int/tme/ (accessed on 12 June 2021).
  15. WHO. Countries; WHO Regional Office for Europe: Copenhagen, Denmark, 2021; Available online: http://www.euro.who.int/en/countries (accessed on 12 June 2021).
  16. Union Nations. DESA/Population Dynamics. World Population Prospects 2019. Available online: https://population.un.org/wpp/ (accessed on 12 June 2021).
  17. World Prison Brief. World Prison Brief Data: Europe. Available online: http://www.prisonstudies.org/map/europe (accessed on 12 June 2021).
  18. Richard Lowry. VassarStats: Website for Statistical computation. Available online: http://vassarstats.net/index.html (accessed on 12 June 2021).
  19. WHO. Definitions and Reporting Framework for Tuberculosis—2013 Revision (Updated December 2014); World Health Organization: Geneva, Switzerland, 2014. [Google Scholar]
  20. WHO. Prisons and Health; WHO Regional Office for Europe: Copenhagen, Denmark, 2014. [Google Scholar]
  21. Lee, D.; Lal, S.S.; Komatsu, R.; Zumla, A.; Atun, R. Global fund financing of tuberculosis services delivery in prisons. J. Infect Dis. 2012, 205 (Suppl. S2), S274–S283. [Google Scholar] [CrossRef] [PubMed]
  22. Grady, J.; Maeurer, M.; Atun, R. Tuberculosis in prisons: Anatomy of global neglect. Eur. Respir. J. 2011, 38, 752–754. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Ruddy, M.; Balabanova, Y.; Graham, C.; Fedorin, I.; Malomanova, N.; Elisarova, E.; Kuznetznov, S.; Gusarova, G.; Zakharova, S.; Melentyev, A.; et al. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax 2005, 60, 130–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Stern, V. The House of the Dead Revisited: Prisons, Tuberculosis and Public Health in the Former Soviet Bloc. In the Return of the White Plague: Global Poverty and the “New” Tuberculosis; Zumla, A., Gandy, M., Eds.; Verso: London, UK, 2003; pp. 178–194. [Google Scholar]
  25. Chaves, F.; Dronda, F.; Alonso-Sanz, M.; Gonzalez-Lopez, A.; Eisenach, K. A longitudinal study of transmission of tuberculosis in a large prison population. Am. J. Respir. Crit. Care Med. 1997, 155, 719–725. [Google Scholar] [CrossRef] [PubMed]
  26. Larouzé, B.; Ventura, M.; Sánchez, A.R.; Diuana, V. Tuberculose nos presídios brasileiros: Entre a responsabilização estatal e a dupla penalização dos detentos. Cad. Saúde Pública 2015, 31, 1127–1130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Kamarulzaman, A.; Reid, S.E.; Schwitters, A.; Wiessing, L.; El-Bassel, N.; Dolan, K. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet 2016, 388, 1115–1126. [Google Scholar] [CrossRef]
  28. Gurbanova, E.; Mehdiyev, R.; Blondal, K.; Altraja, A. Rapid tests reduce the burden of tuberculosis in Azerbaijan prisons: Special emphasis on rifampicin-resistance. Rev. Esp. Sanid. Penit. 2018, 20, 111–120. [Google Scholar] [PubMed]
  29. Gurbanova, E.; Mehdiyev, R.; Blondal, K.; Altraja, A. Predictors of cure in rifampicin-resistant tuberculosis in prison settings with low loss to follow-up. Int. J. Tuberc. Lung Dis. 2016, 20, 645–651. [Google Scholar] [CrossRef] [PubMed]
  30. Gegia, M.; Kalandadze, I.; Madzgharashvili, M.; Furin, J. Developing a human rights-based program for tuberculosis control in Georgian prisons. Health Hum. Rights 2011, 13, E73–E81. [Google Scholar] [PubMed]
  31. Binswanger, I.A.; Stern, M.F.; Deyo, R.A.; Heagerty, P.J.; Cheadle, A.; Elmore, J.G.; Koepsell, T.D. Release from prison—A high risk of death for former inmates. N. Engl. J. Med. 2007, 356, 157–165. [Google Scholar] [CrossRef] [PubMed]
  32. WHO. The End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015; World Health Organization: Geneva, Switzerland, 2014. [Google Scholar]
Figure 1. Countries/states selected for case analysis based on the availability of TB reporting forms. TB: tuberculosis; WHO: World Health Organization.
Figure 1. Countries/states selected for case analysis based on the availability of TB reporting forms. TB: tuberculosis; WHO: World Health Organization.
Ijerph 18 09566 g001
Figure 2. Notification rate of incident TB cases in the penitentiary sector per 100,000 population, WHO European Region, 2018. TB: tuberculosis; WHO: World Health Organization.
Figure 2. Notification rate of incident TB cases in the penitentiary sector per 100,000 population, WHO European Region, 2018. TB: tuberculosis; WHO: World Health Organization.
Ijerph 18 09566 g002
Figure 3. Trends in TB notification rates in the civilian and penitentiary sectors, WHO European Region, 2014–2018. TB: tuberculosis; WHO: World Health Organization. a EECA country. Note: TB notification rate: number of new and relapse tuberculosis cases registered and reported per 100,000 population.
Figure 3. Trends in TB notification rates in the civilian and penitentiary sectors, WHO European Region, 2014–2018. TB: tuberculosis; WHO: World Health Organization. a EECA country. Note: TB notification rate: number of new and relapse tuberculosis cases registered and reported per 100,000 population.
Ijerph 18 09566 g003aIjerph 18 09566 g003b
Figure 4. Relative risks of developing TB among prisons’ inmates compared to civilian population, WHO European Region, 2014–2018. TB: tuberculosis; WHO: World Health Organization.
Figure 4. Relative risks of developing TB among prisons’ inmates compared to civilian population, WHO European Region, 2014–2018. TB: tuberculosis; WHO: World Health Organization.
Ijerph 18 09566 g004
Table 1. Completeness of TB reporting for civilian and penitentiary sectors via The WHO global TB data collection system, WHO European Region countries.
Table 1. Completeness of TB reporting for civilian and penitentiary sectors via The WHO global TB data collection system, WHO European Region countries.
a. Number of New and Relapse TB Cases, 2014–2018
CountryCivilian SectorPenitentiary SectorStatus
2014201520162017201820142015201620172018
Albania40441541249543740383Y
Andorra6441200000Y
Armenia a130311511018825720262091614Y
Austria6190Y
Azerbaijan a54905228490549754822298228254256216Y
Belarus a365830902684225310712197106Y
Belgium85191696789635121920Y
Bosnia and Herzegovina11941091666240Y
Bulgaria177415991503139213075120221616Y
Croatia49144950Y
CyprusN
Czechia4584894974741619142522Y
DenmarkN
Estonia23019718016814069835Y
FinlandN
France443346104774616565Y
Georgia a3099307029262539227210182575843Y
GermanyN
GreeceN
GreenlandN
Hungary789728109Y
Iceland80Y
Ireland29229529330129450000Y
Israel35627852Y
ItalyN
Kazakhstan a14,28213,42311,83812,06312,479962583484386353Y
Kyrgyzstan a62336779681064886198157248216199140Y
Latvia68566460952253333221Y
Lithuania142413541312121457413554Y
Luxembourg373029324210000Y
Malta453250420000Y
Monaco0000Y
Montenegro1127911Y
Netherlands79884586375778416514197Y
North Macedonia280278260206214443103Y
NorwayN
Poland63876065592753655025152172216170171Y
Portugal219820531833172818125361393244Y
Republic of Moldova a393734843398325929331211241739989Y
Romania14,65214,06412,63312,20511,472209161157105114Y
Russian Federation a91,02589,21882,79776,34470,96711,31510,372961081667291Y
San Marino000000Y
Serbia96986474473063715151184Y
Slovakia29929126421021171718Y
Slovenia142129118000Y
SpainN
SwedenN
Switzerland5274Y
Tajikistan a567758045866579456051309099101121Y
Turkey12,96612,41312,03511,69611,421142137151125155Y
Turkmenistan aN
Ukraine a30,24528,97428,13326,48525,74514561177919744767Y
United Kingdom658158215766522643332722Y
Uzbekistan aN
b. Number of TB Patients Who Started on One of the FLD Treatment Schemes, 2012–2016
CountryCivilian SectorPenitentiary SectorStatus
2012201320142015201620122013201420152016
Albania40547040240940622403Y
Andorra9064405000Y
Armenia a13411228120289686192326148Y
AustriaN
Azerbaijan a43413973138912921270275321234183194Y
Belarus a3298293526482458207612799586747Y
Belgium8558568338959553022341018Y
Bosnia and Herzegovina1257119410919074210Y
Bulgaria213618781744157814884425452022Y
CroatiaN
Cyprus551Y
Czechia5364524534814922016141813Y
DenmarkN
Estonia218210189163158416598Y
FinlandN
FranceN
Georgia a32452994278127802666393104816149Y
GermanyN
GreeceN
GreenlandN
Hungary1161101684711144Y
IcelandN
Ireland33634528326528621500Y
Israel50629531726131052Y
ItalyN
Kazakhstan a15,51413,40011,79113,3727611056682634Y
Kyrgyzstan a5533561059695910125121170162Y
Latvia8237646316095604940443332Y
Lithuania142813471238118311263145443626Y
Luxembourg37 1Y
Malta414900000000Y
Monaco3000Y
Montenegro107119112790011Y
Netherlands906796782833850182014414Y
North Macedonia34530927727826018443Y
NorwayN
Poland70576791636960545904204220131142195Y
Portugal24932336219820531833466139Y
Republic of Moldova a4073374733582903290913014210189139Y
Romania16,31315,04814,32113,74712,304112140204161155Y
Russian Federation a80,59471,67467,14671,31764,591907211,627999091078546Y
San Marino00Y
Serbia1171116310328687222621131411Y
Slovakia3233682982882622027201717Y
Slovenia1381391421290000Y
SpainN
SwedenN
SwitzerlandN
Tajikistan a566451515047522252541471121027670Y
Turkey13,40913,04712,79112,21911,851126123142143166Y
Turkmenistan aN
Ukraine a29,34628,01621,27023,01521,618158217101024877997Y
United Kingdom810672606469577356493533432926Y
Uzbekistan a13,783349Y
−: not reported; EECA: east European central Asia; N: excluded from the analysis; TB: tuberculosis; Y: included in the analysis; WHO: World Health Organization a EECA country.
Table 2. Notification rate of incident TB cases and year-to-year percentage changes in TB notification rates, WHO European Region, 2014–2018.
Table 2. Notification rate of incident TB cases and year-to-year percentage changes in TB notification rates, WHO European Region, 2014–2018.
a. Civilian Sector
CountryNotification Rate of Incident TB Cases per 100,000 PopulationAnnual Change in Notification Rate of Incident TB Cases (%)
201420152016201720182014–20152015–20162016–20172017–2018Average
Albania13.914.214.116.915.22.6−0.818.2−10.82.3
Andorra7.65.15.21.32.6−39.00.9−138.269.3−23.5
Armenia a44.939.534.928.224.4−12.8−12.5−21.2−14.4−14.1
Azerbaijan a57.954.550.550.748.6−6.1−7.50.4−4.4−4.3
Belarus a 38.732.728.523.9 −16.8−14.0−17.3−14.8
Belgium7.68.18.57.87.86.74.8−8.3−0.50.7
Bosnia and Herzegovina33.530.8 20.1−8.4 −12.0
Bulgaria24.622.321.119.718.1−9.8−5.5−7.0−8.4−7.4
Croatia11.5 10.7 −3.9
Czech Republic4.34.64.74.53.96.51.6−4.8−14.2−2.7
Estonia17.515.013.712.910.6−15.3−8.8−6.7−19.3−11.8
France 6.97.17.47.3 3.53.1−1.31.8
Georgia a77.877.974.765.156.90.1−4.1−13.8−13.4−7.5
Hungary8.1 7.5 6.1 −6.9
Ireland6.26.36.26.36.10.7−1.31.8−3.6−0.6
Israel4.53.5 −26.3 −26.3
Kazakhstan a81.975.866.066.468.2−7.7−13.90.62.8−4.5
Kyrgyzstan a108.1115.7114.5107.5120.86.8−1.1−6.311.72.8
Latvia34.133.431.026.8 −2.0−7.5−14.4 −7.7
Lithuania48.246.345.242.136.4−4.1−2.4−7.2−14.6−6.8
Luxembourg6.75.35.05.57.0−22.8−5.08.523.71.1
Malta10.67.511.79.812.5−34.644.2−17.825.04.3
Monaco0.00.0 0.0 0.0
Montenegro17.912.6 −35.0 −35.0
Netherlands4.75.05.14.54.65.41.8−13.43.4−0.7
North Macedonia13.513.412.59.910.3−0.8−6.8−23.43.8−6.6
Poland16.715.915.514.113.3−5.1−2.2−9.8−5.9−5.6
Portugal20.519.717.716.817.7−3.8−10.8−5.75.5−3.6
Republic of Moldova a96.985.883.980.672.5−12.1−2.3−4.0−10.6−7.0
Romania73.570.964.062.158.9−3.6−10.2−3.0−5.3−5.4
Russian Federation a63.662.357.853.248.9−2.1−7.5−8.2−8.5−6.4
San Marino 0.00.00.0 0.00.00.0
Serbia10.99.88.48.37.2−11.1−14.6−1.6−13.8−9.7
Slovakia5.55.44.93.94.7−2.8−9.8−22.920.1−3.8
Slovenia6.96.25.7 −9.8−9.1 −9.0
Tajikistan a68.068.067.265.061.70.0−1.1−3.3−5.3−2.4
Turkey16.915.915.214.513.9−5.9−4.6−4.4−4.3−4.7
Ukraine a67.565.063.460.058.3−3.8−2.4−5.6−2.9−3.6
United Kingdom10.18.98.87.97.1−12.9−1.5−10.4−11.0−8.6
EECA67.264.360.256.453.1−4.4−6.6−6.6−6.0−5.7
Non-EECA17.214.914.013.612.7−14.6−5.8−3.4−6.8−7.4
All Countries38.834.932.631.229.1−10.6−6.7−4.4−7.2−7.0
b. Penitentiary Sector
CountryNotification Rate of Incident TB Cases per 100,000 PopulationAnnual Change in Notification Rate of Incident TB Cases (%)
201420152016201720182014–20152015–20162016–20172017–2018Average
Albania76.90.049.2147.756.8−100.0 109.9−95.5−7.3
Andorra0.00.00.00.00.00.00.00.00.00.0
Armenia a662.8509.8184.7328.3395.9−26.2−101.557.518.7−12.1
Azerbaijan a1580.01115.81217.61266.51117.9−34.88.73.9−12.5−8.3
Belarus a 359.3344.1275.8301.4 −4.4−22.18.9−5.7
Belgium297.4109.3161.4188.3160.1−100.139.015.4−16.3−14.3
Bosnia and Herzegovina65.7119.2 0.059.5 −100.0
Bulgaria597.9261.8277.7220.3229.3−82.65.9−23.24.0−21.3
Croatia114.9 0.0 −100.0
Czech Republic85.891.162.3112.8102.06.0−38.059.4−10.14.4
Estonia181.8296.6281.6107.1200.049.0−5.2−96.662.42.4
France 91.397.895.296.7 6.9−2.71.61.9
Georgia a973.8844.0610.7625.0473.4−14.3−32.42.3−27.8−16.5
Hungary47.6 47.4 92.0 17.9
Ireland37.30.00.00.00.0−100.0 0.00.0−100.0
Israel24.19.9 −89.0 −89.0
Kazakhstan a1857.41164.9967.11102.91002.3−46.7−18.613.1−9.6−14.3
Kyrgyzstan a2081.13038.52602.42238.71623.437.8−15.5−15.1−32.1−6.0
Latvia1031.3748.5754.2557.8 −32.10.8−30.2 −18.5
Lithuania660.0557.4513.6818.3718.8−16.9−8.246.6−13.02.2
Luxembourg152.40.00.00.00.0−100.0 0.00.0−100.0
Malta0.00.00.00.00.00.00.00.00.00.0
Monaco0.00.0 0.0 0.0
Montenegro64.274.6 15.0 15.0
Netherlands37.211.637.768.024.0−116.3117.559.0−104.0−10.4
Poland192.4218.2302.3230.3230.812.632.6−27.20.24.7
Portugal378.5421.9261.3237.7348.910.9−47.9−9.538.4−2.0
Republic of Moldova a1765.71809.42228.81275.41165.72.420.8−55.8−9.0−9.9
Romania699.0567.8579.0466.0553.3−20.82.0−21.717.2−5.7
Russian Federation a1683.61543.31503.81335.91259.7−8.7−2.6−11.8−5.9−7.0
San Marino 0.00.00.0 0.00.00.0
Serbia145.8145.8103.175.037.00.0−34.7−31.8−70.6−29.0
Slovakia284.3209.7211.9219.2204.0−30.41.03.4−7.2−8.0
Slovenia0.00.00.0 0.00.0 0.0
Tajikistan a1300.0900.0990.0748.1806.7−36.89.5−28.07.5−11.2
North Macedonia153.8148.1111.1323.9100.0−3.8−28.8107.0−117.5−10.2
Turkey89.476.975.353.855.3−15.0−2.2−33.52.6−11.3
Ukraine a1982.81875.71405.21222.21424.2−5.6−28.9−14.015.3−7.9
United Kingdom43.235.129.023.828.3−20.7−19.1−19.817.4−10.0
EECA1703.91491.41403.61254.51192.8−13.3−6.1−11.2−5.0−8.5
Non-EECA158.2128.1132.5116.3107.4−21.13.4−13.1−7.9−9.2
All Countries1084.6920.7861.3759.9682.2−16.4−6.7−12.5−10.8−10.9
EECA: east European central Asia; WHO: World Health Organization. Note: TB notification rate: number of new and relapse tuberculosis cases registered and reported per 100,000 population. a EECA country; in bold are the countries groups averages
Table 3. Notifications of new and relapse TB cases in the civilian and penitentiary sectors and relative risks (RR) of developing TB for inmates in relation to the civilian population, WHO European Region, 2014–2018.
Table 3. Notifications of new and relapse TB cases in the civilian and penitentiary sectors and relative risks (RR) of developing TB for inmates in relation to the civilian population, WHO European Region, 2014–2018.
CountryN&R Notified, nN&R Notified, Civilian Sector, n a N&R Notified, Penitentiary Sector, n RR (95% CI)Reported Year
Albania44043733.74 (1.20–11.64)2018
Andorra22002018
Armenia b7347201416.15 (9.53–27.38)2018
Austria619619002016
Azerbaijan b5038482221622.78 (19.89–26.09)2018
Belarus b2359225310612.56 (10.34–15.26)2018
Belgium9168962023.96 (15.39–37.30)2017
Bosnia and Herzegovina666666002018
Bulgaria132313071612.33 (7.54–20.18)2018
Croatia449449002016
Czechia4994742525.19 (16.85–37.66)2017
Estonia145140518.83 (7.72–45.90)2018
France483947746512.93 (10.12–16.51)2017
Georgia b23152272437.86 (5.82–10.62)2018
Hungary73772896.33 (3.28–12.21)2016
Iceland88002014
Ireland294294002018
Israel280278210.19 (2.50–41.45)2015
Kazakhstan b128312,47935314.55 (13.10–16.17)2018
Kyrgyzstan b6338619814013.24 (11.21–15.63)2018
Latvia5435222120.68 (13.39–31.95)2017
Lithuania126812145419.29 (14.70–25.30)2017
Luxembourg4242002018
Malta4242002017
Monaco00002015
Montenegro807915.92 (0.82–42.50)2015
Netherlands79178475.22 (2.48–10.97)2018
North Macedonia21721439.71 (3.11–30.33)2018
Poland5196502517117.35 (14.90–20.20)2018
Portugal185618124421.38 (15.86–28.83)2018
Republic of Moldova b302229338916.16 (13.1–19.93)2018
Romania15,58611,4721149.35 (7.78–11.24)2018
Russian Federation b78,25870,967729125.46 (24.85–26.07)2018
San Marino00002018
Serbia64163745.11 (1.91–13.65)2018
Slovakia2282101856.66 (35.03–91.64)2017
Slovenia118118002016
Switzerland53152749.16 (3.43–24.49)2015
Tajikistan b5726560512112.98 (10.85–15.53)2018
Turkey11,57611,4211553.97 (3.39–4.65)2018
Ukraine b26,51225,74576724.12 (22.46–25.90)2018
United Kingdom52485226223.0 (1.98–4.57)2017
CI: confidence interval; EECA: east European central Asia; N&R: new and relapse TB cases; RR: relative risks; TB: tuberculosis; WHO: World Health Organization. a Reference data for risk comparison. b EECA country.
Table 4. Favourable and unfavourable TB treatment outcomes for civilians and inmates on first-line drug treatment schemes, 2012–2016 cohorts, WHO European Region.
Table 4. Favourable and unfavourable TB treatment outcomes for civilians and inmates on first-line drug treatment schemes, 2012–2016 cohorts, WHO European Region.
a. Civilian Sector
CountryOverall, nFavourable Outcome, n (%)Unfavourable OutcomeNot Evaluated, n (%)Last Reported Cohort
Failure, n (%)Died, n (%)LTFU, n (%)
Albania406355 (87.4)3 (0.7)10 (2.5)20 (4.9)18 (4.4)2016
Andorra43 (75.0)0 (0.0)1 (25.0)0 (0.0)0 (0.0)2016
Armenia a861695 (80.7)18 (2.1)48 (5.6)99 (11.5)1 (0.1)2016
Azerbaijan a12701048 (82.5)71 (5.6)16 (1.3)113 (8.9)22 (1.7)2016
Belarus a20761849 (89.1)44 (2.1)111 (5.3)68 (3.3)4 (0.2)2016
Belgium955782 (81.9)0 (0.0)58 (6.1)63 (6.6)52 (5.4)2016
Bosnia and Herzegovina907505 (55.7)13 (1.4)64 (7.1)3 (0.3)322 (35.5)2016
Bulgaria14881270 (85.3)15 (1.0)122 (8.2)81 (5.4)0 (0.0)2016
Cyprus5537 (67.3)0 (0.0)0 (0.0)0 (0.0)18 (32.7)2016
Czechia492335 (68.1)1 (0.2)82 (16.7)54 (11.0)20 (4.1)2016
Estonia158125 (79.1)3 (1.9)26 (16.5)2 (1.3)2 (1.3)2016
Georgia a26662226 (83.5)52 (2.0)112 (4.2)232 (8.7)44 (1.7)2016
Hungary847598 (70.6)18 (2.1)101 (11.9)78 (9.2)52 (6.1)2015
Ireland286103 (36.0)0 (0.0)16 (5.6)2 (0.7)165 (57.7)2016
Israel261216 (82.8)1 (0.4)19 (7.3)8 (3.1)17 (6.5)2015
Kazakhstan a13,37212,188 (91.1)396 (3.0)666 (5.0)122 (0.9)0 (0.0)2015
Kyrgyzstan a59104838 (81.9)108 (1.8)351 (5.9)591 (10.0)22 (0.4)2016
Latvia560477 (85.2)0 (0.0)52 (9.3)28 (5.0)3(0.5)2016
Lithuania1126949 (84.3)12 (1.1)109 (9.7)51 (4.5)5 (0.4)2016
Luxembourg370 (0.0)0 (0.0)1 (2.7)0 (0.0)36 (97.3)2014
Malta4937 (75.5)0 (0.0)1 (2.0)3 (6.1)8 (16.3)2013
Monaco0000002014
Montenegro7973 (92.4)0 (0.0)3 (3.8)3 (3.8)0 (0.0)2015
Netherlands850741 (87.2)0 (0.0)30 (3.5)33 (3.9)46 (5.4)2016
North Macedonia260230 (88.5)1 (0.4)18 (6.9)10 (3.8)1 (0.4)2016
Poland59043187 (54.0)3 (0.1)578 (9.8)361(6.1)1775 (30.1)2016
Portugal18331298 (70.8)0 (0.0)131 (7.1)60 (3.3)344 (18.8)2016
Republic of Moldova a29092398 (82.4)70 (2.4)292 (10.0)114 (3.9)35 (1.2)2016
Romania12,30410,578 (86.0)193 (1.6)996 (8.1)518 (4.2)19 (0.2)2016
Russian Federation a64,59147,524 (73.6)3761 (5.8)7098 (11.0)3213 (5.0)2995 (4.6)2016
San Marino0000002015
Serbia722583 (80.7)6 (0.8)64 (8.9)26 (3.6)43 (6.0)2016
Slovakia262224 (85.5)0 (0.0)27 (10.3)2 (0.8)9 (3.4)2016
Slovenia129105 (81.4)0 (0.0)21 (16.3)0 (0.0)3 (2.3)2015
Tajikistan a52544690 (89.3)103 (2.0)223 (4.2)195 (3.7)43 (0.8)2016
Turkey11,85110,323 (87.1)31 (0.3)698 (5.9)311 (2.6)488 (4.1)2016
Ukraine a21,61816,756 (77.5)1326 (6.1)2112 (9.8)1339 (6.2)85 (0.4)2016
United Kingdom56494554 (80.6)0 (0.0)315 (5.6)262 (4.6)518 (9.2)2016
Uzbekistan a13,78311,667 (84.6)272 (2.0)615 (4.5)677 (4.9)552 (4.0)2012
b. Penitentiary sector
CountryOverall, nFavourable Outcome, n (%)Unfavourable OutcomeNot Evaluated, n (%)Last Reported Cohort
Failure, n (%)Died, n (%)LTFU, n (%)
Albania32 (66.7)0 (0.0)0 (0.0)0 (0.0)1 (33.3)2016
Andorra0000002016
Armenia a88 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2016
Azerbaijan a194177 (91.2)2 (1.0)10 (5.2)5 (2.6)0 (0.0)2016
Belarus a4745 (95.7)1 (2.1)1 (2.1)0 (0.0)0 (0.0)2016
Belgium1811 (61.1)0 (0.0)0 (0.0)4 (22.2)3 (16.7)2016
Bosnia and Herzegovina0000002016
Bulgaria2221 (95.5)0 (0.0)0 (0.0)1 (4.5)0 (0.0)2016
Cyprus10 (0.0)0 (0.0)0 (0.0)1 (100.0)0 (0.0)2016
Czechia1311 (84.6)0 (0.0)1 (7.7)0 (0.0)1 (7.7)2016
Estonia88 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2016
Georgia a4937 (75.5)1 (2.0)1 (2.0)3 (6.1)7 (14.3)2016
Hungary42 (50.0)0 (0.0)0 (0.0)2 (50.0)0 (0.0)2015
Ireland0000002016
Israel22 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2015
Kazakhstan a634503 (79.3)44 (6.9)8 (1.3)79 (12.5)0 (0.0)2015
Kyrgyzstan a162130 (80.2)4 (2.5)9 (5.6)18 (11.1)1 (0.6)2016
Latvia3228 (87.5)1 (3.1)1 (3.1)1 (3.1)1 (3.1)2016
Lithuania2618 (69.2)0 (0.0)2 (7.7)6 (23.1)0 (0.0)2016
Luxembourg11 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2014
Malta0000002013
Monaco0000002014
Montenegro11 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2015
Netherlands146 (42.9)0 (0.0)0 (0.0)4 (28.6)4 (28.6)2016
North Macedonia32 (66.7)0 (0.0)0 (0.0)1 (33.3)0 (0.0)2016
Poland195113 (57.9)0 (0.0)4 (2.1)3 (1.5)75 (38.5)2016
Portugal3918 (46.2)0 (0.0)1 (2.6)0 (0.0)20 (51.3)2016
Republic of Moldova a139117 (84.2)7 (5.0)2 (1.4)9 (6.5)4 (2.9)2016
Romania155145 (93.5)0 (0.0)6 (3.9)4 (2.6)0 (0.0)2016
Russian Federation a85464811 (56.3)841 (9.8)325 (3.8)328 (3.8)2241 (26.2)2016
San Marino0000002015
Serbia117 (63.6)0 (0.0)1 (9.1)3 (27.3)0 (0.0)2016
Slovakia1717 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)2016
Slovenia0000002015
Tajikistan a7061 (87.1)1 (1.4)5 (7.1)3 (4.3)0 (0.0)2016
Turkey166139 (83.7)1 (0.6)7 (4.2)14 (8.4)5 (3.0)2016
Ukraine a997478 (47.9)434 (43.5)28 (2.8)48 (4.8)9 (0.9)2016
United Kingdom2616 (61.5)0 (0.0)1 (3.8)2 (7.7)7 (26.9)2016
Uzbekistan a349238 (68.2)38 (10.9)38 (10.9)10 (2.9)25 (7.2)2012
LTFU: lost to follow-up; TB: tuberculosis; WHO: World Health Organization. a EECA country.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Dadu, A.; Ciobanu, A.; Hovhannesyan, A.; Alikhanova, N.; Korotych, O.; Gurbanova, E.; Mehdiyev, R.; Doltu, S.; Gozalov, O.; Ahmedov, S.; et al. Tuberculosis Notification Trends and Treatment Outcomes in Penitentiary and Civilian Health Care Sectors in the WHO European Region. Int. J. Environ. Res. Public Health 2021, 18, 9566. https://doi.org/10.3390/ijerph18189566

AMA Style

Dadu A, Ciobanu A, Hovhannesyan A, Alikhanova N, Korotych O, Gurbanova E, Mehdiyev R, Doltu S, Gozalov O, Ahmedov S, et al. Tuberculosis Notification Trends and Treatment Outcomes in Penitentiary and Civilian Health Care Sectors in the WHO European Region. International Journal of Environmental Research and Public Health. 2021; 18(18):9566. https://doi.org/10.3390/ijerph18189566

Chicago/Turabian Style

Dadu, Andrei, Ana Ciobanu, Araksya Hovhannesyan, Natavan Alikhanova, Oleksandr Korotych, Elmira Gurbanova, Rafael Mehdiyev, Svetlana Doltu, Ogtay Gozalov, Sevim Ahmedov, and et al. 2021. "Tuberculosis Notification Trends and Treatment Outcomes in Penitentiary and Civilian Health Care Sectors in the WHO European Region" International Journal of Environmental Research and Public Health 18, no. 18: 9566. https://doi.org/10.3390/ijerph18189566

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop